Effectiveness and Safety of New Botanical Component-LFCO- Compared With Existing TTO in Clinical Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01930565|
Recruitment Status : Completed
First Posted : August 29, 2013
Last Update Posted : August 29, 2013
In an 8 week double blind randomized controlled split-face studies, we tried to compare the clinical efficacy, safety and histopathological changes between Lactobacillus fermented Chamaecypris obtusa (LFCO) and existing tea tree oil (TTO)
Basically, this is a split face study - one side of face randomly assigned was applied with LFCO and the other side with TTO in same patients.
|Condition or disease||Intervention/treatment||Phase|
|Acne Vulgaris||Other: LFCO application Other: TTO application||Not Applicable|
Screening of natural compounds for the development of anti-acne therapeutic agents has been steadily required considering various side effects of acne medications.However, previous studies have mainly focused on experimental tests without clinical trials and histopathological analysis.
To compare the clinical efficacy, safety and histopathological changes between Lactobacillus fermented Chamaecypris obtusa (LFCO) and existing tea tree oil (TTO)
Total thirty four patients were instructed to apply 5 % LFCO to the involved areas of randomly allocated side and 5 % TTO extract to the other side for 8 weeks in a double blind split-face clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Comparison of Clinical and Histological Effects Between Lactobacillus Fermented Chamaecypris Obtusa and Tea Tree Oil for the Treatment of Mild to Moderate Acne: an 8-week Double Blind, Randomized Controlled, Split-face Study|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Experimental: LFCO application
We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
Other: LFCO application
Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
Other Name: LFCO containg creams applied to acne lesions
Active Comparator: TTO application
To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
Other: TTO application
Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
Other Name: TTO containg creams applied to acne lesions
- Number of inflammatory and non-inflammatory acne lesions [ Time Frame: total 8 weeks after baseline ]Compared to baseline, number inflammatory and non-inflammatory acne lesions were counted to check out the effectiveness & safety of two botanical compounds
- Patient's subjective assessments for comfortableness & efficacy [ Time Frame: 8 weeks after baseline ]Patients are required to report subjective assessments for comfortableness & efficacy for two creams they used
- Sebum secretion assessment [ Time Frame: 8 weeks after baseline ]Patients' sebum secretion from face was measured by sebumeter to detect sebum secretion changes after applying two components.
- Histopathologic analysis [ Time Frame: 8 weeks after baseline ]changes of tissue after application of two creams
- Adverse effects [ Time Frame: 8 weeks after baseline ]patients' reportings for severe side effects after application of two creams was monitored.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01930565
|Korea, Republic of|
|Department of Dermatology, Seoul National University College of Medicine|
|Seoul, Korea, Republic of, 110-744|
|Study Chair:||Dae Hun Sun, MD||Seoul National University Hospital|